(NASDAQ: ABSI) Absci's forecast annual revenue growth rate of 151.23% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 90.96%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.86%.
Absci's revenue in 2025 is $4,138,000.On average, 5 Wall Street analysts forecast ABSI's revenue for 2025 to be $995,372,261, with the lowest ABSI revenue forecast at $442,587,035, and the highest ABSI revenue forecast at $2,186,768,712. On average, 5 Wall Street analysts forecast ABSI's revenue for 2026 to be $5,696,812,851, with the lowest ABSI revenue forecast at $442,587,035, and the highest ABSI revenue forecast at $11,513,243,819.
In 2027, ABSI is forecast to generate $9,663,499,153 in revenue, with the lowest revenue forecast at $442,587,035 and the highest revenue forecast at $15,194,491,388.